Theravance Biopharma Analyst Ratings
Theravance Biopharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/17/2022 | 24.78% | SVB Leerink | $12 → $14 | Maintains | Outperform |
| 11/08/2022 | 69.34% | HC Wainwright & Co. | $12 → $19 | Maintains | Buy |
| 07/25/2022 | -10.87% | Morgan Stanley | $11 → $10 | Maintains | Underweight |
| 05/23/2022 | 6.95% | SVB Leerink | → $12 | Initiates Coverage On | → Outperform |
| 03/02/2022 | -1.96% | Morgan Stanley | $10 → $11 | Maintains | Underweight |
| 02/24/2022 | 6.95% | HC Wainwright & Co. | $8 → $12 | Maintains | Buy |
| 11/05/2021 | 6.95% | JP Morgan | $7 → $12 | Upgrades | Underweight → Neutral |
| 09/16/2021 | -10.87% | Morgan Stanley | $14 → $10 | Maintains | Underweight |
| 09/16/2021 | -28.7% | HC Wainwright & Co. | $21 → $8 | Maintains | Buy |
| 09/16/2021 | -10.87% | SVB Leerink | $29 → $10 | Maintains | Outperform |
| 08/25/2021 | 24.78% | Morgan Stanley | $27 → $14 | Downgrades | Overweight → Underweight |
| 08/24/2021 | 24.78% | Cowen & Co. | $42 → $14 | Downgrades | Outperform → Market Perform |
| 08/24/2021 | 158.47% | SVB Leerink | $37 → $29 | Maintains | Outperform |
| 08/24/2021 | 60.43% | Needham | $32 → $18 | Maintains | Buy |
| 08/24/2021 | 87.17% | HC Wainwright & Co. | $32 → $21 | Maintains | Buy |
| 08/04/2021 | 229.77% | SVB Leerink | $36 → $37 | Maintains | Outperform |
| 07/16/2021 | 140.64% | Morgan Stanley | $28 → $27 | Maintains | Overweight |
| 06/28/2021 | 220.86% | SVB Leerink | $39 → $36 | Maintains | Outperform |
| 05/13/2021 | 149.55% | Morgan Stanley | $30 → $28 | Maintains | Overweight |
| 05/05/2021 | 185.2% | Needham | $40 → $32 | Maintains | Buy |
| 05/05/2021 | 247.59% | SVB Leerink | $40 → $39 | Maintains | Outperform |
| 04/01/2021 | 256.51% | SVB Leerink | $41 → $40 | Maintains | Outperform |
| 03/01/2021 | 167.38% | Morgan Stanley | $31 → $30 | Maintains | Overweight |
| 02/24/2021 | 265.42% | SVB Leerink | $35 → $41 | Maintains | Outperform |
| 12/16/2020 | 176.29% | Morgan Stanley | $32 → $31 | Maintains | Overweight |
| 11/24/2020 | 167.38% | Evercore ISI Group | → $30 | Reinstates | → Outperform |
| 11/06/2020 | 211.94% | SVB Leerink | $40 → $35 | Maintains | Outperform |
| 10/14/2020 | — | Morgan Stanley | Upgrades | Equal-Weight → Overweight | |
| 08/10/2020 | 167.38% | Piper Sandler | $35 → $30 | Maintains | Overweight |
| 08/10/2020 | 158.47% | Morgan Stanley | $30 → $29 | Maintains | Equal-Weight |
| 07/07/2020 | 158.47% | JP Morgan | → $29 | Initiates Coverage On | → Overweight |
| 06/15/2020 | 167.38% | Morgan Stanley | → $30 | Initiates Coverage On | → Equal-Weight |
| 05/13/2020 | 274.33% | Cowen & Co. | → $42 | Initiates Coverage On | → Outperform |
| 02/25/2020 | 185.2% | HC Wainwright & Co. | $30 → $32 | Maintains | Buy |
| 02/25/2020 | 211.94% | Piper Sandler | $40 → $35 | Maintains | Overweight |
| 11/06/2019 | 60.43% | Baird | $22 → $18 | Upgrades | Underperform → Neutral |
| 10/29/2019 | 122.82% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 02/08/2018 | 327.81% | Leerink Swann | $45 → $48 | Maintains | Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 11/17/2022 | 24.78% | SVB Leerink | $12 → $14 | 維護 | 跑贏大盤 |
| 11/08/2022 | 69.34% | HC Wainwright公司 | $12 → $19 | 維護 | 買 |
| 07/25/2022 | -10.87% | 摩根士丹利 | $11 → $10 | 維護 | 體重不足 |
| 05/23/2022 | 6.95% | SVB Leerink | → $12 | 開始承保 | →跑贏大盤 |
| 03/02/2022 | -1.96% | 摩根士丹利 | $10 → $11 | 維護 | 體重不足 |
| 02/24/2022 | 6.95% | HC Wainwright公司 | $8 → $12 | 維護 | 買 |
| 11/05/2021 | 6.95% | 摩根大通 | $7 → $12 | 升級 | 減重→中性 |
| 09/16/2021 | -10.87% | 摩根士丹利 | $14 → $10 | 維護 | 體重不足 |
| 09/16/2021 | -28.7% | HC Wainwright公司 | $21 → $8 | 維護 | 買 |
| 09/16/2021 | -10.87% | SVB Leerink | $29 → $10 | 維護 | 跑贏大盤 |
| 08/25/2021 | 24.78% | 摩根士丹利 | $27 → $14 | 評級下調 | 增持→減持 |
| 08/24/2021 | 24.78% | 考恩公司 | $42 → $14 | 評級下調 | 跑贏→市場表現 |
| 08/24/2021 | 158.47% | SVB Leerink | $37 → $29 | 維護 | 跑贏大盤 |
| 08/24/2021 | 60.43% | 李約瑟 | $32 → $18 | 維護 | 買 |
| 08/24/2021 | 87.17% | HC Wainwright公司 | $32 → $21 | 維護 | 買 |
| 08/04/2021 | 229.77% | SVB Leerink | $36 → $37 | 維護 | 跑贏大盤 |
| 07/16/2021 | 140.64% | 摩根士丹利 | $28 → $27 | 維護 | 超重 |
| 06/28/2021 | 220.86% | SVB Leerink | $39 → $36 | 維護 | 跑贏大盤 |
| 05/13/2021 | 149.55% | 摩根士丹利 | $30 → $28 | 維護 | 超重 |
| 05/05/2021 | 185.2% | 李約瑟 | $40 → $32 | 維護 | 買 |
| 05/05/2021 | 247.59% | SVB Leerink | $40 → $39 | 維護 | 跑贏大盤 |
| 04/01/2021 | 256.51% | SVB Leerink | $41 → $40 | 維護 | 跑贏大盤 |
| 03/01/2021 | 167.38% | 摩根士丹利 | $31 → $30 | 維護 | 超重 |
| 02/24/2021 | 265.42% | SVB Leerink | $35 → $41 | 維護 | 跑贏大盤 |
| 12/16/2020 | 176.29% | 摩根士丹利 | $32 → $31 | 維護 | 超重 |
| 11/24/2020 | 167.38% | Evercore ISI集團 | → $30 | 恢復 | →跑贏大盤 |
| 11/06/2020 | 211.94% | SVB Leerink | $40 → $35 | 維護 | 跑贏大盤 |
| 10/14/2020 | — | 摩根士丹利 | 升級 | 等重→超重 | |
| 08/10/2020 | 167.38% | 派珀·桑德勒 | $35 → $30 | 維護 | 超重 |
| 08/10/2020 | 158.47% | 摩根士丹利 | $30 → $29 | 維護 | 等重 |
| 07/07/2020 | 158.47% | 摩根大通 | → $29 | 開始承保 | →超重 |
| 06/15/2020 | 167.38% | 摩根士丹利 | → $30 | 開始承保 | →等重 |
| 05/13/2020 | 274.33% | 考恩公司 | → $42 | 開始承保 | →跑贏大盤 |
| 02/25/2020 | 185.2% | HC Wainwright公司 | $30 → $32 | 維護 | 買 |
| 02/25/2020 | 211.94% | 派珀·桑德勒 | $40 → $35 | 維護 | 超重 |
| 11/06/2019 | 60.43% | 貝爾德 | $22 → $18 | 升級 | 表現不佳的→中性 |
| 10/29/2019 | 122.82% | HC Wainwright公司 | → $25 | 開始承保 | →購買 |
| 02/08/2018 | 327.81% | 利林克·斯旺 | $45 → $48 | 維護 | 跑贏大盤 |
What is the target price for Theravance Biopharma (TBPH)?
Theravance Biophma(TBPH)的目標價是多少？
The latest price target for Theravance Biopharma (NASDAQ: TBPH) was reported by SVB Leerink on November 17, 2022. The analyst firm set a price target for $14.00 expecting TBPH to rise to within 12 months (a possible 24.78% upside). 6 analyst firms have reported ratings in the last year.
SVB Leerink於2022年11月17日報道了Theravance Biophma(納斯達克：tbph)的最新目標價。這家分析公司將目標價定為14.00美元，預計TBPH將在12個月內上漲(可能上漲24.78%)。6家分析公司在過去一年公佈了評級。
What is the most recent analyst rating for Theravance Biopharma (TBPH)?
Theravance Biophma(TBPH)的最新分析師評級是多少？
The latest analyst rating for Theravance Biopharma (NASDAQ: TBPH) was provided by SVB Leerink, and Theravance Biopharma maintained their outperform rating.
對Theravance Biophma(納斯達克代碼：TBPH)的最新分析師評級由SVB Leerink提供，Theravance Biophma維持其表現優於大盤的評級。
When is the next analyst rating going to be posted or updated for Theravance Biopharma (TBPH)?
Theravance Biophma(TBPH)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Theravance Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Theravance Biopharma was filed on November 17, 2022 so you should expect the next rating to be made available sometime around November 17, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閲公共財務報表，與Theravance Biophma的高管和客户交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Theravance Biophma的最後一次評級是在2022年11月17日提交的，所以你應該預計下一次評級將在2023年11月17日左右的某個時候提供。
Is the Analyst Rating Theravance Biopharma (TBPH) correct?
分析師對Theravance Biophma(TBPH)的評級正確嗎？
While ratings are subjective and will change, the latest Theravance Biopharma (TBPH) rating was a maintained with a price target of $12.00 to $14.00. The current price Theravance Biopharma (TBPH) is trading at is $11.22, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Theravance Biophma(TBPH)評級保持不變，目標價在12.00美元至14.00美元之間。Theravance Biophma(TBPH)目前的交易價格為11.22美元，超出了分析師的預測區間。